Scarica l'app Stockscreener
0.1682
2.04%
-0.0035
Propanc Biopharma Inc Borsa (PPCB) Ultime notizie
Propanc Biopharma's lead asset PRP shows >85% tumor growth inhibition in preclinical pancreatic models - marketscreener.com
Propanc Biopharma highlights potential of lead asset PRP - TipRanks
Propanc Biopharma’S Lead Asset Prp Shows >85% Tumor Growth Inhibition In Preclinical Pancreatic Models - TradingView
Deadliest cancer stuck at 13% survival: new PRP therapy targets spread - Stock Titan
PPCB Technical Analysis & Stock Price Forecast - Intellectia AI
Propanc Biopharma Announces Board Change and New Appointment - TipRanks
Propanc Biopharma appoints Dr. Ralf Brandt to board following Dr. Kenyon’s retirement - Investing.com Nigeria
Propanc Biopharma appoints Dr. Ralf Brandt to board following Dr. Kenyon’s retirement By Investing.com - Investing.com South Africa
Propanc Biopharma (PPCB) adds oncology expert Ralf Brandt to board as Kenyon retires - Stock Titan
[EFFECT] Propanc Biopharma, Inc. SEC Filing - Stock Titan
Propanc Biopharma files four new patent applications for cancer treatment By Investing.com - Investing.com South Africa
Propanc Biopharma files four new patent applications for cancer treatment - Investing.com
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results - The Manila Times
Propanc Biopharma, Inc. SEC 10-Q Report - TradingView
Certain Warrants of Propanc Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 10-FEB-2026. - marketscreener.com
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market - The Manila Times
Lab tests: Propanc’s PRP slowed tumor growth 85%, human trial planned - Stock Titan
Propanc Biopharma files fourth patent application in two months By Investing.com - Investing.com Australia
Propanc Biopharma files fourth patent application in two months - Investing.com
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations - marketscreener.com
Propanc Biopharma Accelerates IP Momentum: Files Fourth - GlobeNewswire
New cancer approach: Propanc races to lock in proenzyme drug patents - Stock Titan
PPCB Forecast — Price Prediction for 2026. Should I Buy PPCB? - Intellectia AI
Propanc Biopharma files new patent for synthetic cancer treatment - Investing.com
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia - The Manila Times
Propanc Biopharma, Inc. Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia - marketscreener.com
Propanc Biopharma files new patent for synthetic cancer treatment By Investing.com - Investing.com Canada
Propanc Biopharma advances pancreatic cancer treatment toward clinical trials By Investing.com - Investing.com Nigeria
Propanc Biopharma advances pancreatic cancer treatment toward clinical trials - Investing.com
Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer - The Manila Times
Two pancreatic proenzymes could offer new options for deadly cancer - Stock Titan
Propanc Biopharma plans phase 1b trial for cancer treatment PRP By Investing.com - Investing.com Canada
Propanc Biopharma plans phase 1b trial for cancer treatment PRP - Investing.com
Propanc Biopharma Provides Shareholder Update - The Manila Times
Cancer-focused biopharma Propanc plans 2026 human trial, fibrosis work - Stock Titan
Contrasting GRAIL (NASDAQ:GRAL) and Propanc Biopharma (OTCMKTS:PPCB) - Defense World
Propanc Biopharma Receives Nasdaq Minimum Bid Price Notice - TipRanks
Propanc Biopharma Received Notice of Noncompliance - TradingView — Track All Markets
Propanc Biopharma (NASDAQ: PPCB) details 2M-share Series C resale - Stock Titan
Propanc Biopharma files prospectus for resale of 2 million shares by selling stockholderSEC filing - marketscreener.com
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology - The Globe and Mail
Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal - The Manila Times
Study tests enzyme mix that may disrupt deadly pancreatic tumors' support cells - Stock Titan
Propanc Biopharma, Inc. (PPCB) Stock Forecast & Price Prediction 2025–2030 - CoinCodex
Propanc Biopharma Shares Gain After Seeking Patent Protection for New Cancer and Fibrosis Treatments - MSN
Propanc Biopharma Inc. (PPCB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Propanc Biopharma, Inc. (PPCB) -6.3% in After-hours: Shares Slide Amid Investigation Announcement - Stocks Telegraph
Propanc Biopharma Investigates 'Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs - The Manila Times
Propanc Biopharma (Nasdaq: PPCB) targets fibrosis, cancer via PRP EMT research - Stock Titan
Views of Wall Street’s Leading Experts on Propanc Biopharma Inc - setenews.com
Propanc Biopharma (PPCB) Stock Analysis Report | Financials & Insights - Benzinga
Propanc Biopharma files patents for resistant cancer and fibrosis treatments By Investing.com - Investing.com Australia
Propanc Biopharma stock rises after filing for patents to treat resistant cancer By Investing.com - Investing.com South Africa
Propanc Biopharma stock rises after filing for patents to treat resistant cancer - Investing.com Australia
Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis - The Manila Times
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):